2. >>Content

What’s Next? Five Things To Look Out For In June

 
• By Dean Rudge

Generics Bulletin previews the most noteworthy and anticipated events for June 2025.

What's Next Image
Source: Norstella/Citeline

Today, 1 June, Celltrion’s Stoboclo and Osenvelt (denosumab-bmwo) biosimilars – approved by the FDA in February – are set to follow Sandoz’s late May entry into the US denosumab market.

Under the terms of a settlement reached with Amgen earlier this year that paved the way...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Content

What’s Next? Five Things To Look Out For In July

 
• By Dean Rudge

Generics Bulletin previews the most noteworthy and anticipated events for July 2025.

What’s Next? Five Things To Look Out For In June

 
• By Dean Rudge

Generics Bulletin previews the most noteworthy and anticipated events for June 2025.

More from Generics Bulletin

CivicaScript Offers Generic Tecfidera To US Pharmacies For $47 Per Bottle

 
• By Urtė Fultinavičiūtė

As CivicaScript continues its mission to make treatments more accessible with its newly launched generic Tecfidera at a low price, generic drug coverage remains under threat, showed AAM analysis.

Sandoz Starts Construction On $440m Slovenian Biosimilars Plant

 
• By Dave Wallace

Sandoz has begun constructing a major biosimilars manufacturing facility in Slovenia that is set to become operational in 2028. A $440m investment in the project adds to local biosimilars initiatives that together total over $1bn, helping Sandoz to move out of the shadow of former parent Novartis.

Torrent Acquires JB Chem In 2025’s Biggest Deal For Indian Pharma

 
• By Vibha Ravi

Torrent Pharma’s JB Chemicals acquisition follows the Curatio deal and Boehringer brands buyout. The second-biggest deal ever and the largest in 2025 among domestic pharma companies helps Torrent fill white spaces in areas like nephrology and gives an entry into the CDMO segment.